Latent tuberculosis infection (LTBI) treatment completion and complication in Leeds, UK

Background: Successful LTBI treatment (Rx) is essential in controlling TB in low incidence countries. Reported LTBI Rx completion rate in USA, Canada and UK is around 50% [1.2]. In Leeds we run an active screening programme for both new entrant and contact screening with a great emphasis on patient education and close follow-up. Methods: We conducted a retrospective review of all the LTBI patients (excluding those starting Rx pre anti-TNF) who were offered and accepted Rx in 2009 in Leeds. We looked at the completion rate, side effects (SE) of the Rx and reasons for not completing Rx. Results: 184 LTBI patients were offered and accepted Rx. 89% (163/184) of the patients successfully completed the Rx. View this table: Table 1 Of those not completing the Rx 38% (8/21) had moved out of Leeds and another 38% (8/21) failed to follow up without known reason, only 3 patients stopped Rx due to SE. Conclusion: Good compliance is achievable with patient education and close follow-up. Treatment side effects of LTBI are usually mild and self resolving. References: * 1. Horsburgh C.R. Jr et al. Latent TB infection treatment acceptance and completion in the United States and Canada. Chest 2010;137(2):401-9. * 2. Rennie T.W. et al. Patient choice promotes adherence in preventive treatment for latent tuberculosis. Eur Respir J 2007;30:728-735.